LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of the first FDA-approved treatment for lactose intolerance, today announces it will be presenting two posters of additional data from the Phase 2b trial of RP-G28 at Digestive Disease Week, June 2-5, 2018 in Washington, D.C.
“Both of these posters represent a significant advancement in the lactose intolerance field. The current management of lactose intolerant persons focuses on exclusion of dairy products which is inconvenient and can lead to unintended consequences,” said William D. Chey, M.D., professor of medicine and co-director of the Michigan Bowel Control Program at University of Michigan, Ann Arbor, Mich. “We report an entirely novel approach to treating lactose intolerance.”
- Poster #1048: “A Novel Tool to Assess Symptoms of Lactose Intolerance and Define Meaningful Patient Benefit” will be presented on June 4, 2018.
- Poster #1884: “Improvement of Clinical Symptoms of Lactose Intolerance with a Novel Prebiotic Galacto-Oligosaccharide, RP-G28,” will be presented on June 5, 2018.
“As we examine the totality of our Phase 2b trial results, we are encouraged by the therapeutic potential RP-G28 may have in treating lactose intolerance,” said Andrew J. Ritter, co-founder and president of Ritter Pharmaceuticals, Inc. “We continue to build upon this data in the development of our Phase 3 program, for which we plan to initiate our first pivotal trial in the second quarter of 2018.”
About Digestive Disease Week
Highlighting the most relevant, up-to-date and cutting-edge science, Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. DDW is jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT). In 2018, it is held from June 2-5 in Washington, D.C.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The Company’s lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions of people worldwide. RP-G28 has been studied in Phase 2 trials, and is expected to commence Phase 3 clinical development in the second quarter of 2018. The Company is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including: gastrointestinal diseases, cancer, metabolic, and liver disease.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of Ritter Pharmaceuticals’ management, including statements regarding the timing and commencement of our first Phase 3 clinical trial. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.
CONTACT: Contacts Investor Contact: Shaun Novin 310-203-1000 firstname.lastname@example.org Media Contact: Jules Abraham CoreIR 917-885-7378 email@example.com